Results 1 to 10 of about 79,837 (298)
Antibody drug conjugates [PDF]
Indian Journal of Medical and Paediatric Oncology, 2020 Antibody drug conjugates (ADCs) are chemically engineered drugs consisting of monoclonal antibody (mAb) and cytotoxic compound attached chemically by a linker. Upon attachment to a specific target antigen, ADC enters into the cell and payload is released,
Stalin Bala, Siva K Prasad
doaj +7 more sources
Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting [PDF]
Frontiers in Immunology, 2023 Cancerous B cells are almost indistinguishable from their non-malignant counterparts regarding their surface antigen expression. Accordingly, the challenge to be faced consists in elimination of the malignant B cell population while maintaining a ...
Katrin Schoenfeld +5 more
doaj +2 more sources
HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer [PDF]
Cancer MedicineBackground HER2‐targeted antibody‐drug conjugates (ADCs) have dramatically advanced breast cancer outcomes. Two HER2‐targeted ADCs, trastuzumab deruxtecan and trastuzumab emtansine, are currently approved for use in breast cancer, with > 60 other ...
Seohyuk Lee +5 more
doaj +2 more sources
Corneal pseudomicrocysts following claudin-6 antibody-drug conjugate infusion [PDF]
American Journal of Ophthalmology Case ReportsPurpose: To report a case of bilateral corneal pseudomicrocysts associated with infusions of a novel antibody-drug conjugate targeting claudin-6, called TORL-1-23.
Laura Matuszewska +5 more
doaj +2 more sources
Antibody–drug conjugates [PDF]
Proceedings of the National Academy of Sciences, 2013 Ideally, targeted therapies attack diseased cells while leaving healthy ones alone. It’s a strategy that could result in more effective treatments for cancer (or other diseases) with fewer toxic side effects than traditional chemotherapies. A burgeoning class of targeted therapies, called antibody–drug conjugates (ADC), deliver dual therapies in a ...
Beck, Alain, Reichert, Janice M.
+8 more sources
Antibody-Drug Conjugates [PDF]
Pharmaceutical Research, 2015 Antibody-drug conjugates (ADCs) are an exciting and new class of therapeutic modalities that have gained significant traction over the past few years – specifically in the field of oncology. With the recent approvals of CD-30 directed Adcetris® (brentuximab vedotin) and the Her2 targeted Kadcyla® (ado-trastuzumab emtansine) and hundreds of other ADCs ...
Ashutosh A, Kulkarni +1 more
+7 more sources
Antibody-Drug Conjugate-Induced Pneumonitis: A Growing Threat [PDF]
Journal of Immunotherapy and Precision OncologyKathy L. Chan +2 more
doaj +2 more sources
Practical oncology, 2023 This article is a literature review of the available data on the history of origin, mechanism of action, and the main currently available conjugate-linked monoclonal antibodies. The use of conjugate-linked monoclonal antibodies in the therapy of both solid and hematological malignancies is a promising direction of anti-tumor therapy.
E.O. Stepanova +2 more
+5 more sources
Pharmaceuticals, 2022 Although there have been extensive research and progress on the discovery of anticancer drug over the years, the application of these drugs as stand-alone therapy has been limited by their off-target toxicities, poor pharmacokinetic properties, and low ...
Audrey Nathania Johan, Yi Li
doaj +1 more source
Antibody-Drug Conjugates [PDF]
Journal of Nihon University Medical Association, 2017 Abstract Antibody–drug conjugates (ADCs) are designed with the purpose of delivering small-molecule cytotoxic drug to antigen-expressing tumor cells by harnessing the specificity, biodistribution, and pharmacokinetics of antibodies. ADCs are comprised of three components: the antibody, the linker, and the cytotoxic agent.
Amit Kumar +4 more
+5 more sources